

This PANNA newsletter will also be available at the website: www.pannastudy.com

A newsletter will be issued once per 4 months to update you on the status of the study and inclusions.

Investigators Meeting in Glasgow Monday November 8

We are very pleased that many of you were present and that we had a lively discussion.

Summary of the meeting

David welcomed everybody; Angela gave an update of the study (see the website and attachment for the power point presentation).

Discussions:

How to convince the women to come to the unit for the post partum curve?
Costs for child-day care can be invoiced. We have not (yet) decided on increasing the fee for the subjects. In some countries this would be considered not ethical. If you think recruitment would be easier in case of increased fee, please contact Angela to discuss the possibilities.

PK curves from women who take their once daily regimen in the evening.
St Georges is able to collect samples during the night (compliments from everybody!); other centres would need to switch the women to morning intake for a limited time period (see power point presentation).

First PRELIMINARY results of women on raltegravir, darunavir, atazanavir, ritonavir were presented. As these data are confidential they are not presented in this news letter. If you are interested, let Angela know and she will send data to you personally. However: be aware that we only analyzed a limited number of patients for each drug.

Amendment

Be aware that the new informed consent has to be used from now on.

List of compounds under investigation

panna


Etravirine, Intelence, ETV
Emtricitabine, Emtriva or FTC
Tenofovir, Viread, TDF
Atazanavir, Reyataz, ATV
Fosamprenavir, Telzir, FPV
Darunavir, Prezista, DRV
Tipranavir, Aptivus, TPV
Indinavir, Crixivan, IDV
Raltegravir, Isentress, RAL
Enfuvirtide, Fuzeon, T-20
Maraviroc, Celsentri, MVC
Efavirenz, Stocrin, EFV*
*UK/Ireland only

Centres

All centres in *The Netherlands; UK; Italy; Ireland* are open for inclusion.
Germany: 4 centres open for inclusion.
Belgium: submitted.
Portugal: working on submission.
France: working on submission.
Spain: an additional centre (Granada) will participate.
Italy: possibly Milano will participate.
Canada: ethics approval.

Inclusions

21 subjects signed informed consent.



Have a nice Christmas season!

Angela Colbers
Project manager
E-mail: A.Colbers@akf.umcn.nl
HIVPharmacology@akf.umcn.nl
Radboud University Nijmegen Medical Centre, Internal postal code 864,
Department of Pharmacy,
P.O. Box 9101, 6500 HB Nijmegen
Phone: + 31 (0)24 - 361 64 05
Fax: + 31 (0)24- 366 87 55